All In Biotech

Drug Trial Radar · NCT06945419

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

219

Actual

Start

Apr 23, 2025

Primary completion

Aug 5, 2026

Study completion Aug 5, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Conditions

  • Healthy
  • Overweight
  • Obesity
  • Type 2 Diabetes

Interventions

  • LY4086940Drug

    Administered orally

  • PlaceboDrug

    Administered orally

  • LY4086940Drug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Week 9

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida

  • Clinical Pharmacology of Miami

    Miami, Florida

  • Fortrea Clinical Research Unit

    Dallas, Texas

  • Endeavor Clinical Trials

    San Antonio, Texas

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.